, Columnist
Teva Is Losing Credibility
It's time for a plan to deal with problems, not more promises.
This article is for subscribers only.
If you've got bad news to deliver, it's always better to do it all at once, rather than parcel it out.
Earlier this year, for example, Teva Pharmaceutical Industries Ltd. cut its 2017 revenue guidance by $1.5 billion due to underperformance of its flagship generics business. That guidance, however, did not include generic competition for the most important form of its best-selling multiple sclerosis drug Copaxone.